Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dositinib in EGFR-mutated NSCLC
NCT07231068Phase 2Recruiting
- Sponsor
- Genuine Biotech
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of dositinib mesylate in non-small cell lung cancer (NSCLC), sponsored by Genuine Biotech. Started Oct 2022; status: recruiting.
02
Drugs
dositinib mesylate
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07231068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07231068.